KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to $96,000.

  • TherapeuticsMD's Depreciation & Amortization (CF) changed negligibly% to $96,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $387,000, marking a year-over-year decrease of 63.00%. This contributed to the annual value of $509,000 for FY2024, which is 44.79% down from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Depreciation & Amortization (CF) is $96,000, which was down 0.00% from $96,000 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Depreciation & Amortization (CF) ranged from a high of $1.0 million in Q2 2021 and a low of -$2.4 million during Q4 2021.
  • Its 3-year average for Depreciation & Amortization (CF) is $156,273, with a median of $100,000 in 2024.
  • As far as peak fluctuations go, TherapeuticsMD's Depreciation & Amortization (CF) slumped by 329.09% in 2021, and later surged by 392.59% in 2024.
  • TherapeuticsMD's Depreciation & Amortization (CF) (Quarterly) stood at -$2.4 million in 2021, then skyrocketed by 113.12% to $309,000 in 2022, then surged by 106.15% to $637,000 in 2023, then tumbled by 84.30% to $100,000 in 2024, then remained steady at $96,000 in 2025.
  • Its Depreciation & Amortization (CF) was $96,000 in Q3 2025, compared to $96,000 in Q2 2025 and $95,000 in Q1 2025.